stockportfolio.pro
iRhythm Holdings, Inc. (IRTC)
Healthcare · Medical Devices · NasdaqGS
iRhythm Holdings, Inc. revenue & earnings — last 10 fiscal years
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $64.07M | $99.13M | $147.28M | $214.55M | $265.17M | $322.82M | $410.92M | $492.68M | $591.84M | $747.14M |
| Gross profit | $43.19M | $70.93M | $108.48M | $162.07M | $194.89M | $213.57M | $281.63M | $331.81M | $407.53M | $527.25M |
| Net income | $-20.90M | $-29.74M | $-50.38M | $-54.57M | $-43.83M | $-101.36M | $-116.16M | $-123.41M | $-113.29M | $-44.55M |
| Net margin | -32.6% | -30.0% | -34.2% | -25.4% | -16.5% | -31.4% | -28.3% | -25.0% | -19.1% | -6.0% |
Source: iRhythm Holdings, Inc. SEC filings (10-K). 12 years of history available in the interactive view.
What growth is priced into IRTC stock?
At today's market cap of $3.65B, iRhythm Holdings, Inc. is priced for free-cash-flow growth of about 30.7% per year for 10 years (assuming a 10% discount rate and 2.5% terminal growth, base FCF $34.52M from the FY ending 2025-12-31). For comparison, revenue 23%/yr, computed from its SEC filings. This is a reverse DCF — a translation of the price into a growth assumption you can judge, not a fair value and not advice. Change the assumptions yourself in the interactive view →
Explore 12 years of iRhythm Holdings, Inc. financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track IRTC in your portfolio →
iRhythm Holdings, Inc. financial history by metric
About iRhythm Holdings, Inc.
iRhythm Holdings, Inc., a digital healthcare company, engages in the design, development, and commercialization of device-based technology that provides ambulatory cardiac monitoring services to diagnose arrhythmias in the United States. The company offers Zio ambulatory cardiac monitoring services, including long-term and short-term continuous monitoring and mobile cardiac telemetry monitoring services. It also provides Zio Monitor System, a prescription-only remote electrocardiogram (ECG) monitoring system consisting a patch ECG monitor that records the electric signal from the heart continuously for up to 14 days; Zio XT System, a prescription-only remote ECG monitoring system that consists of the Zio XT patch that records the electric signal from the heart continuously for up to 14 days; and Zio ECG Utilization Software System, which supports the capture and analysis of ECG data. In addition, the company offers Zio AT System, a prescription-only remote ECG monitoring system, which consists of the Zio AT patch that records the electric signal from the heart continuously for up to 14 days, as well as incorporates the Zio AT wireless gateway to provide connectivity between the patch and the ZEUS System during the patient wear period. It has a development collaboration agreement with BioIS to develop and commercialize pulse oximetry, accelerometry, and trending non-invasive blood pressure technologies for use within ambulatory cardiac monitoring products and services. The company was formerly known as iRhythm Technologies, Inc. and changed its name to iRhythm Holdings, Inc. in January 2026. iRhythm Holdings, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.
iRhythm Holdings, Inc. — frequently asked questions
What is iRhythm Holdings, Inc.'s revenue?
iRhythm Holdings, Inc. (IRTC) reported revenue of $747.14M for fiscal year 2025, up 26.2% from the prior year, according to its SEC filings.
Is iRhythm Holdings, Inc. profitable?
No — IRTC reported a net loss of $-44.55M in fiscal 2025.
What is IRTC's P/E ratio?
iRhythm Holdings, Inc. trades at a price-to-earnings ratio of about 0.0 based on the latest data in our nightly-refreshed cache.
How fast is iRhythm Holdings, Inc. growing?
IRTC's revenue grew at roughly 23.0% per year over the last five fiscal years (compound annual growth rate), computed from SEC-filed statements.
How much debt does iRhythm Holdings, Inc. have?
As of fiscal year 2025, IRTC carried roughly $649.50M in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is iRhythm Holdings, Inc.'s gross margin?
IRTC's gross margin was 70.6% in fiscal 2025 — gross profit of $527.25M on revenue of $747.14M.
What is iRhythm Holdings, Inc.'s market cap?
iRhythm Holdings, Inc. (IRTC) has a market capitalization of about $3.65B, based on the latest data in our nightly-refreshed cache.
When does iRhythm Holdings, Inc.'s fiscal year end?
IRTC's fiscal year ends in December. Its most recent annual filing covers the fiscal year ending 2025-12-31.
What growth is priced into IRTC stock?
At today's market cap of $3.65B, iRhythm Holdings, Inc. is priced for free-cash-flow growth of about 30.7% per year for 10 years (assuming a 10% discount rate and 2.5% terminal growth, base FCF $34.52M from the FY ending 2025-12-31). For comparison, revenue 23%/yr, computed from its SEC filings.
Where does this data come from?
All figures are computed from iRhythm Holdings, Inc.'s official SEC filings (10-K and 10-Q), covering 12 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.